Anti-Fibrinolytic Drugs - South Africa

South Africa

South Africa is projected to experience a significant growth in revenue within the Anti-Fibrinolytic Drugs market.
By 2024, it is estimated that the revenue will reach €48.09m.
This growth is expected to continue steadily with an annual growth rate (CAGR 2024-2029) of 4.39%.
As a result, the market volume is projected to reach €59.62m by 2029.
When compared globally, it is important to note that United States will generate the highest revenue within the market.
In 2024, United States is expected to generate a substantial revenue of €9,141.00m.
This indicates the dominant position of the United States in the global Anti-Fibrinolytic Drugs market.
South Africa's market for anti-fibrinolytic drugs is experiencing a surge due to rising cases of bleeding disorders.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Fibrinolytic Drugs market in South Africa has been experiencing significant growth in recent years.

Customer preferences: Anti-fibrinolytic drugs are mainly used to control bleeding during surgical procedures. The preference for these drugs has been increasing due to the growing number of surgeries performed in South Africa, especially in the fields of cardiology, neurology, and orthopedics.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in South Africa is the increasing use of tranexamic acid, which is a type of anti-fibrinolytic drug. This drug has been found to be effective in controlling bleeding in a wide range of surgical procedures. Another trend in the market is the growing popularity of topical anti-fibrinolytic agents, which are used to control bleeding during dental procedures.

Local special circumstances: The South African healthcare system is characterized by a high burden of disease, limited resources, and significant disparities in access to healthcare services. These factors have contributed to the growing demand for anti-fibrinolytic drugs in the country. In addition, the increasing number of private healthcare facilities in South Africa has also contributed to the growth of the market.

Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in South Africa can be attributed to several macroeconomic factors. These include the increasing burden of disease in the country, the growing number of surgical procedures being performed, and the increasing adoption of new technologies in the healthcare sector. In addition, the growing demand for healthcare services in the country, coupled with the increasing availability of healthcare financing options, has also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.